Citigroup Maintains Buy on Coherus BioSciences, Raises Price Target to $31

Citigroup maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and raises the price target from $27 to $31.

Benzinga · 11/07/2019 12:24

Citigroup maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and raises the price target from $27 to $31.